Arg-Gly-Asp TFA

CAS No. ——

Arg-Gly-Asp TFA ( —— )

Catalog No. M19317 CAS No. ——

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 58 Get Quote
10MG 100 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Arg-Gly-Asp TFA
  • Note
    Research use only, not for human use.
  • Brief Description
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
  • Description
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    ATM/ATR
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    460.36
  • Molecular Formula
    C14H23F3N6O8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N.FC(F)(F)C(=O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hersel U, et al. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials. 2003 Nov;24(24):4385-415.
molnova catalog
related products
  • AZD-6738

    AZD-6738 (AZD6738, Ceralasertib) is a potent and selective inhibitor of ATR with IC50 of 1 nM; shows no significant activity for ATM, DNA-PK and mTOR.

  • BAY-1895344

    BAY-1895344 is a potent, selective, orally active ATR inhibitor with low-nanomolar potency; potently inhibits the proliferation of a broad spectrum of human tumor cell lines with mean IC50 of 78 nM; inhibits hydroxyurea-induced H2AX phosphorylation, exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models.Blood Cancer,Phase 1 Clinical

  • KU-60019

    KU-60019 is an improved analogue of KU-55933, and is a potent, specific inhibitor of ATM kinase with IC50 of 6.3 nM, 270- and 1,600-fold selectivity over DNA-PKcs and ATR.